Drug Trial Radar · NCT06496581
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Sep 12, 2024
Primary completion
Feb 1, 2033
Study completion Aug 1, 2039
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic treatment compared to standard systemic treatment alone in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who do not present with a satisfactory response characterized by a serum prostatic specific antigen (PSA) level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level).
Conditions
- Prostate Cancer Metastatic
Interventions
177Lu-PMSA-617Drug
Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
Standard of CareDrug
ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From randomization to death due to any cause, up to 8.5 years
- Radiographic progression-free survival (rPFS)Time frame: From randomization to radiographic progression or death, up to 8.5 years
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Institut de Cancérologie de l'Ouest
Angers, France · Not yet recruiting
Institut Bergonié
Bordeaux, France · Not yet recruiting
CHRU Brest
Brest, France · Not yet recruiting
Centre Francois Baclesse
Caen, France · Not yet recruiting
CHU Henri Mondor
Créteil, France · Not yet recruiting
Centre Georges-François Leclerc
Dijon, France · Not yet recruiting
CHU Grenoble
Grenoble, France · Not yet recruiting
Centre Léon Berard
Lyon, France · Not yet recruiting
Institut Paoli-Calmettes
Marseille, France · Recruiting
CHRU Nancy
Nancy, France · Not yet recruiting
Centre Antoine Lacassagne
Nice, France · Not yet recruiting
Hôpital Cochin
Paris, France · Not yet recruiting
Hôpital Saint Louis
Paris, France · Not yet recruiting
Institut Curie
Paris, France · Not yet recruiting
Centre Eugène Marquis
Rennes, France · Recruiting
Centre Henri Becquerel
Rouen, France · Not yet recruiting
CHU Rouen
Rouen, France · Not yet recruiting
Institut Curie
Saint-Cloud, France · Not yet recruiting
Institut de Cancérologie de l'Ouest
Saint-Herblain, France · Not yet recruiting
CHU Saint Etienne
Saint-Priest-en-Jarez, France · Not yet recruiting
ICANS
Strasbourg, France · Not yet recruiting
IUCT Oncopole
Toulouse, France · Not yet recruiting
CHRU Tours
Tours, France · Not yet recruiting
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France · Not yet recruiting
Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.